JP5814488B2 - ジヒドロピリダジン−3,5−ジオン誘導体 - Google Patents

ジヒドロピリダジン−3,5−ジオン誘導体 Download PDF

Info

Publication number
JP5814488B2
JP5814488B2 JP2015505576A JP2015505576A JP5814488B2 JP 5814488 B2 JP5814488 B2 JP 5814488B2 JP 2015505576 A JP2015505576 A JP 2015505576A JP 2015505576 A JP2015505576 A JP 2015505576A JP 5814488 B2 JP5814488 B2 JP 5814488B2
Authority
JP
Japan
Prior art keywords
methyl
trifluoromethyl
phenyl
hydroxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015505576A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2014142273A1 (ja
Inventor
義仁 大竹
義仁 大竹
直樹 岡本
直樹 岡本
芳幸 小野
芳幸 小野
浩孝 柏木
浩孝 柏木
篤 金原
篤 金原
武雄 原田
武雄 原田
伸行 堀
伸行 堀
佳久 村田
佳久 村田
一生 橘
一生 橘
翔太 田中
翔太 田中
研一 野村
研一 野村
光昭 井出
光昭 井出
栄作 水口
栄作 水口
康弘 市田
康弘 市田
秀一 大友
秀一 大友
直 堀場
直 堀場
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to JP2015505576A priority Critical patent/JP5814488B2/ja
Application granted granted Critical
Publication of JP5814488B2 publication Critical patent/JP5814488B2/ja
Publication of JPWO2014142273A1 publication Critical patent/JPWO2014142273A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/504Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
JP2015505576A 2013-03-13 2014-03-13 ジヒドロピリダジン−3,5−ジオン誘導体 Active JP5814488B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015505576A JP5814488B2 (ja) 2013-03-13 2014-03-13 ジヒドロピリダジン−3,5−ジオン誘導体

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2013051082 2013-03-13
JP2013051082 2013-03-13
JP2013132889 2013-06-25
JP2013132889 2013-06-25
PCT/JP2014/056778 WO2014142273A1 (ja) 2013-03-13 2014-03-13 ジヒドロピリダジン-3,5-ジオン誘導体
JP2015505576A JP5814488B2 (ja) 2013-03-13 2014-03-13 ジヒドロピリダジン−3,5−ジオン誘導体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015182722A Division JP6420738B2 (ja) 2013-03-13 2015-09-16 ジヒドロピリダジン−3,5−ジオン誘導体

Publications (2)

Publication Number Publication Date
JP5814488B2 true JP5814488B2 (ja) 2015-11-17
JPWO2014142273A1 JPWO2014142273A1 (ja) 2017-02-16

Family

ID=51536921

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015505576A Active JP5814488B2 (ja) 2013-03-13 2014-03-13 ジヒドロピリダジン−3,5−ジオン誘導体
JP2015182722A Active JP6420738B2 (ja) 2013-03-13 2015-09-16 ジヒドロピリダジン−3,5−ジオン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015182722A Active JP6420738B2 (ja) 2013-03-13 2015-09-16 ジヒドロピリダジン−3,5−ジオン誘導体

Country Status (29)

Country Link
EP (2) EP2975030B1 (enExample)
JP (2) JP5814488B2 (enExample)
KR (2) KR102072268B1 (enExample)
CN (1) CN105073715B (enExample)
AU (1) AU2014230552B2 (enExample)
BR (1) BR112015022092B1 (enExample)
CA (1) CA2901868C (enExample)
CL (1) CL2015002543A1 (enExample)
CR (1) CR20150505A (enExample)
DK (1) DK2975030T3 (enExample)
ES (1) ES2811126T3 (enExample)
HR (1) HRP20201211T1 (enExample)
HU (1) HUE050577T2 (enExample)
IL (1) IL240825B (enExample)
LT (1) LT2975030T (enExample)
MX (1) MX376532B (enExample)
MY (1) MY174269A (enExample)
NZ (1) NZ711182A (enExample)
PE (1) PE20151535A1 (enExample)
PH (1) PH12015501940A1 (enExample)
PL (1) PL2975030T3 (enExample)
PT (1) PT2975030T (enExample)
RS (1) RS60911B1 (enExample)
RU (1) RU2662832C2 (enExample)
SG (1) SG11201507345RA (enExample)
SI (1) SI2975030T1 (enExample)
TW (2) TWI596095B (enExample)
UA (1) UA118755C2 (enExample)
WO (1) WO2014142273A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016040262A (ja) * 2013-03-13 2016-03-24 中外製薬株式会社 ジヒドロピリダジン−3,5−ジオン誘導体

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107072993B (zh) * 2014-09-12 2021-02-12 中外制药株式会社 含有钠依赖性磷酸转运蛋白抑制剂的药物
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN110885290A (zh) * 2019-12-16 2020-03-17 阿里生物新材料(常州)有限公司 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法
CA3186902A1 (en) 2020-06-26 2021-12-30 Nihon Nohyaku Co., Ltd. Aryltetrahydropyridazine derivative or salt thereof, insecticidal agent containing the compound, and method of use thereof
WO2022221182A1 (en) * 2021-04-12 2022-10-20 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc34a1 function
JPWO2022260064A1 (enExample) 2021-06-08 2022-12-15
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
KR20240125659A (ko) 2021-12-28 2024-08-19 니혼노야쿠가부시키가이샤 아릴테트라히드로피리다진 유도체 또는 그의 염류 및 해당 화합물을 함유하는 살충제 그리고 그 사용 방법
CN119212723A (zh) 2022-05-11 2024-12-27 中外制药株式会社 用于治疗或预防囊性疾病的药物组合物
CN116217862A (zh) * 2023-03-21 2023-06-06 中国农业科学院农业环境与可持续发展研究所 一种可降解生物膜助剂的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1477175B1 (en) * 2002-02-19 2011-04-27 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
CN1662529A (zh) * 2002-06-19 2005-08-31 默克专利有限公司 作为磷酸二酯酶iv抑制剂的噻唑衍生物
EP1967516B1 (en) * 2005-05-18 2009-11-04 Array Biopharma, Inc. 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EP2086944B1 (de) * 2006-11-03 2010-01-13 Basf Se Verfahren zur herstellung von difluormethylpyrazolylcarboxylaten
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
EP2334682B1 (en) * 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
US20130029973A1 (en) 2010-04-28 2013-01-31 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006474A2 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CA2853688C (en) 2011-10-27 2018-06-12 Astellas Pharma Inc. Aminoalkyl-substituted n-thienylbenzamide derivative
HUE050577T2 (hu) * 2013-03-13 2020-12-28 Chugai Pharmaceutical Co Ltd Dihidropiridazin-3,5-dion-származék

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016040262A (ja) * 2013-03-13 2016-03-24 中外製薬株式会社 ジヒドロピリダジン−3,5−ジオン誘導体

Also Published As

Publication number Publication date
AU2014230552A1 (en) 2015-08-13
PH12015501940B1 (en) 2016-01-11
JP6420738B2 (ja) 2018-11-07
NZ711182A (en) 2020-05-29
CA2901868C (en) 2022-05-03
AU2014230552B2 (en) 2017-11-16
WO2014142273A1 (ja) 2014-09-18
PT2975030T (pt) 2020-09-28
JPWO2014142273A1 (ja) 2017-02-16
TWI596095B (zh) 2017-08-21
CR20150505A (es) 2015-10-26
KR102072268B1 (ko) 2020-01-31
KR20150127721A (ko) 2015-11-17
TW201741304A (zh) 2017-12-01
SI2975030T1 (sl) 2020-10-30
ES2811126T3 (es) 2021-03-10
CN105073715A (zh) 2015-11-18
IL240825B (en) 2020-07-30
DK2975030T3 (da) 2020-08-31
EP2975030B1 (en) 2020-07-15
EP2975030A1 (en) 2016-01-20
MX376532B (es) 2025-03-07
HK1212700A1 (zh) 2016-06-17
KR101664460B1 (ko) 2016-10-10
MY174269A (en) 2020-04-01
PH12015501940A1 (en) 2016-01-11
BR112015022092B1 (pt) 2023-04-11
BR112015022092A2 (pt) 2017-07-18
RS60911B1 (sr) 2020-11-30
HUE050577T2 (hu) 2020-12-28
PE20151535A1 (es) 2015-10-28
SG11201507345RA (en) 2015-10-29
KR20160119282A (ko) 2016-10-12
TW201446756A (zh) 2014-12-16
HRP20201211T1 (hr) 2020-11-13
EP3757093A1 (en) 2020-12-30
CL2015002543A1 (es) 2016-02-26
TWI683811B (zh) 2020-02-01
UA118755C2 (uk) 2019-03-11
RU2662832C2 (ru) 2018-07-31
MX2015012537A (es) 2016-02-10
CN105073715B (zh) 2017-12-01
RU2015143507A (ru) 2017-04-19
LT2975030T (lt) 2020-09-25
PL2975030T3 (pl) 2021-01-11
EP2975030A4 (en) 2016-08-03
BR112015022092A8 (pt) 2018-01-23
IL240825A0 (en) 2015-10-29
CA2901868A1 (en) 2014-09-18
JP2016040262A (ja) 2016-03-24

Similar Documents

Publication Publication Date Title
JP5814488B2 (ja) ジヒドロピリダジン−3,5−ジオン誘導体
JP5916975B1 (ja) ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬
EP4577549A1 (en) Compounds and methods for modulating her2
US9499553B2 (en) Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
RU2811864C1 (ru) Фармацевтическое средство, содержащее ингибитор натрийзависимого переносчика фосфата
HK1212700B (en) Dihydropyridazine-3,5-dione derivative
HK1235279A1 (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
HK1235279B (zh) 含有钠依赖性磷酸转运蛋白抑制剂的药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150428

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150428

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150917

R150 Certificate of patent or registration of utility model

Ref document number: 5814488

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250